Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchChlorpheniramineChlorphenira.. (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Chlorpheniramine for COVID-19
3 studies from 37 scientists
806 patients in 2 countries
Significantly lower risk for recovery.
2 studies (both from the same team) show significant benefit.
COVID-19 Chlorpheniramine studies. Dec 2024. c19early.org
0 0.5 1 1.5+ All studies 56% Hospitalization 87% Recovery 56% RCTs 63% Early 56% Favorschlorpheniramine Favorscontrol
Nov 30
Covid Analysis Chlorpheniramine for COVID-19: real-time meta analysis of 3 studies
Significantly lower risk is seen for recovery. 2 studies (both from the same team) show significant benefit. Meta analysis using the most serious outcome reported shows 56% [46‑64%] lower risk. Results are similar for Randomize..
Nov 26
Valerio-Pascua et al., BMC Infectious Diseases, doi:10.1186/s12879-024-10211-8 Mitigating the risks of post-acute sequelae of SARS-CoV-2 infection (PASC) with intranasal chlorpheniramine: perspectives from the ACCROS studies
90% lower PASC (p=0.001). Prospective study of 259 COVID-19 outpatients from the ACROSS-I and ACROSS-III RCTs showing significantly lower long COVID with intranasal chlorpheniramine (iCPM) compared to placebo. 72% of placebo patients experienced at least one PASC ..
Dec 31
2022
Sanchez-Gonzalez et al., Medical Research Archives, doi:10.18103/mra.v10i3.2752 Intranasal Chlorpheniramine Maleate for the treatment of COVID-19: Translational and Clinical Evidence
87% lower hospitalization (p=0.08). Small RCT showing significantly improved recovery with intranasal chlorpheniramine maleate. Authors also perform an In Vitro study showing efficacy with a highly differentiated three-dimensional model of normal, human-derived tracheal/bro..
Oct 18
2022
Valerio-Pascua et al., Research Square, doi:10.21203/rs.3.rs-2167465/v1 Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials
54% faster recovery (p<0.0001). RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The retrospective study included 660 outpatients showing fewer days with general COVID-19 symptoms, cough, anosmia, and ageusia compared to standard of care alone. ..
Oct 18
2022
Valerio-Pascua et al., Research Square, doi:10.21203/rs.3.rs-2167465/v1 Chlorpheniramine Intranasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: The ACCROS Trials
61% improved recovery (p=0.0002) and 74% lower PASC (p=0.001). RCT and retrospective study of chlorpheniramine nasal spray for COVID-19. The RCT included 101 outpatients showing significantly faster recovery with treatment. The retrospective study results are listed separately [Valerio-Pascua]. Long ..
Jan 28
2022
Akash et al., Frontiers in Drug Delivery, doi:10.3389/fddev.2023.1164671 (date from preprint) On a model-based approach to improve intranasal spray targeting for respiratory viral infections
Computational fluid dynamics study of nasal spray administration in 2 subjects showing 100x improvement in nasopharyngeal drug delivery using a new spray placement protocol. The study also found the optimal droplet size range for nasophar..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit